Acrivon Therapeutics, Inc. Annual Share-based Payment Arrangement, Expense in USD from 2021 to 2023

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Acrivon Therapeutics, Inc. quarterly/annual Share-based Payment Arrangement, Expense history and growth rate from 2021 to 2023.
  • Acrivon Therapeutics, Inc. Share-based Payment Arrangement, Expense for the quarter ending June 30, 2024 was $3.57M, a 32.8% increase year-over-year.
  • Acrivon Therapeutics, Inc. Share-based Payment Arrangement, Expense for the twelve months ending June 30, 2024 was $13.2M, a 82.1% increase year-over-year.
  • Acrivon Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2023 was $11.6M, a 432% increase from 2022.
  • Acrivon Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2022 was $2.19M, a 340% increase from 2021.
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Growth (%)
Period Value YoY Chg Change % Start Date End Date Report Filed
2023 $11.6M +$9.43M +432% Jan 1, 2023 Dec 31, 2023 10-K 2024-03-28
2022 $2.19M +$1.69M +340% Jan 1, 2022 Dec 31, 2022 10-K 2024-03-28
2021 $497K Jan 1, 2021 Dec 31, 2021 10-K 2023-03-28
* An asterisk sign (*) next to the value indicates that the value is likely invalid.